MAPS is currently sponsoring MAPP2, the second of two Phase 3 trials to support FDA approval of this breakthrough-designated therapy. In their first Phase 3 study, 88% of participants with severe PTSD experienced a clinically significant reduction in PTSD diagnostic
Depression is the third-leading cause of disability worldwide. Even if successfully treated, however, 80 percent of patients will relapse in the five years following remission. Over 30 percent will fail to respond to at least two antidepressant treatments, and be diagnosed with treatment-resistant
Up to 30% of people with depression don’t respond to treatment with antidepressants. This may be down to differences in biology between patients and the fact that it often takes a long time to respond to the drugs – with some people